Skip to main content Skip to search Skip to main navigation

EMA: Guiding Principles on LLMs, a Category of Generative AI

On 5 September 2024 the EMA and the Heads of Medicine Agencies HMA, published guiding principles that set how EU medicine regulators can use large language models (LLMs), a form of generative AI, focusing on text generation in regulatory science and for regulatory activities. The 10-page document provides high-level recommendations to facilitate LLMs' safe, responsible, and effective use, being of interest to anyone who uses or would like to use such AI models in the future.

"LLMs have enormous transformative potential," says EMA, “but also present challenges: variability in results, returning of irrelevant or inaccurate responses (so-called hallucinations), and potential data security risks." On the other hand, LLMs could be applied to query the extensive documentation regulators receive, to automate knowledge/data mining processes, or as virtual AI assistants in everyday administrative tasks.

Therefore, the document aims to build an understanding of the capabilities and limitations of these applications among staff at regulatory agencies across the EU to harness the potential of LLMs effectively and avoid pitfalls and risks. General ethical considerations, e.g. the rule of law, accountability, security, safety, transparency, non-discrimination, misinformation harms, and malicious uses or copyright issues are included.

Being part of the multiannual AI work plan to 2028 set out by EMA, the guiding principles are considered a living document that will be regularly updated. An EMA factsheet on LLMs can be found here.


Source:

EMA: Guiding principles on the use of LLMs in regulatory science and for medicines regulatory activities

EMA: Factsheet on the 4 principles for safe and responsible use of LLMs

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

The EMA has published a concept paper outlining a future revision of Annex 3 (Manufacture of Radiopharmaceuticals) of the EU GMP Guidelines. The paper was developed in collaboration with PIC/S and adopted by the GMDP Inspectors Working Group (IWG) at its November meeting.

Read more
EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
EU: Agreement on the Pharmaceutical Package

EU: Agreement on the Pharmaceutical Package

On 11 December, the European Commission, the European Parliament, and the Council of the European Union reached a provisional agreement to update Europe's medicinal products regulatory framework.

Read more
EMA: Updated Q&As for Biological Medicinal Products

EMA: Updated Q&As for Biological Medicinal Products

EMA has updated its Q&A on biological medicinal products, addressing topics that previously required clarification or were subject to differing interpretation. The latest revision adds six new questions and updates several existing answers.

Read more
ICH: New Recommendations for the Manufacture of ATMPs

ICH: New Recommendations for the Manufacture of ATMPs

The ICH’s Cell and Gene Therapy Discussion Group (CGTDG), which was established in May 2023, has provided recommendations with regard to future Advanced Therapy Medicinal Products (ATMPs) Related Guidelines.

Read more
GMP Publishing Embarks on a new Digital Chapter

GMP Publishing Embarks on a new Digital Chapter

After months of intensive work, creative ideas, and technical finesse, the time has finally come: the GMP Verlag website has been given a fresh new look.
Read more
Previous
Next